Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 12/20 | 0.50 |
| ▸ | CA1 | P00915 | 11/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 7/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA7 | P43166 | 3/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.42 |
| ▸ | CA3 | P07451 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 2/20 | 0.42 |
| ▸ | CA6 | P23280 | 2/20 | 0.42 |
| ▸ | CA5A | P35218 | 2/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11314889 | 0.98 | CA2 (0.52) | PPARACA2CA1EPHX1CA9 | |
| SCHEMBL7205612 | 0.91 | CA2 (0.60) | PPARACA2CA1CA9CA12 | |
| SCHEMBL7205609 | 0.81 | — | — | |
| SCHEMBL12469021 | 0.80 | CA1 (0.50) | PPARACA2CA1EPHX1 | |
| SCHEMBL3275563 | 0.78 | PPARA (0.47) | PPARACA2CA1EPHX1CA9 | |
| SCHEMBL3794668 | 0.77 | CA2 (0.82) | PPARACA2CA1EPHX1CA9 | |
| SCHEMBL4622863 | 0.77 | CA2 (0.82) | PPARACA2CA1EPHX1CA9 | |
| SCHEMBL1228645 | 0.77 | CA2 (0.82) | PPARACA2CA1EPHX1CA9 | |
| SCHEMBL3124345 | 0.77 | CA2 (0.82) | PPARACA2CA1EPHX1CA9 | |
| SCHEMBL291897 | 0.77 | CA2 (0.82) | PPARACA2CA1EPHX1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569513-B2 | Compound having a triptycene moiety | FUJIFILM CORPORATION (JP) | 2013-10-29 | — | — | US | disclosed |
| US-20110237804-A1 | COMPOUND HAVING A TRIPTYCENE MOIETY | FUJIFILM CORPORATION (JP) | 2011-09-29 | — | — | US | disclosed |
| US-7697095-B2 | Liquid crystal display device | FUJIFILM CORPORATION (JP) | 2010-04-13 | — | — | US | disclosed |
| US-20100072437-A1 | COMPOSITION, COLOR FILTER AND PROCESS FOR PREPARING COLOR FILTER | FUJIFILM CORPORATION (JP) | 2010-03-25 | — | — | US | disclosed |
| US-20080137014-A1 | Liquid Crystal Display Device | FUJIFILM CORPORATION (JP) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237804-A1 | COMPOUND HAVING A TRIPTYCENE MOIETY | CHRM1, H1-2, H1-0 | PPARA 1835/4885CA2 480/4885CA1 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.